Valuation: Penumbra, Inc.

Market Cap 12.85B 11.15B 10.45B 9.52B 17.92B 1,225B 18.2B 123B 47.98B 614B 48.25B 47.2B 2,048B P/E 2026 *
74.1x
P/E 2027 * 53.3x
Enterprise Value 12.4B 10.76B 10.09B 9.19B 17.29B 1,182B 17.56B 119B 46.31B 592B 46.57B 45.56B 1,976B EV / Sales 2026 *
7.78x
EV / Sales 2027 * 6.74x
Free-Float
97.11%
Yield 2026 *
-
Yield 2027 * -
1 day+0.09%
1 week+0.73%
Current month+1.68%
1 month+2.67%
3 months+1.51%
6 months-3.45%
Current year+5.04%
1 week 323.86
Extreme 323.855
327.55
1 month 315.69
Extreme 315.69
327.55
Current year 290
Extreme 290
362.41
1 year 221.26
Extreme 221.26
362.41
3 years 148
Extreme 148
362.41
5 years 114.86
Extreme 114.865
362.41
10 years 56.05
Extreme 56.05
362.41
Manager TitleAgeSince
Chief Executive Officer 64 2004-06-20
President 41 2025-08-31
Director of Finance/CFO 54 2019-12-01
Director TitleAgeSince
Chairman 64 2014-12-31
Chairman 64 2004-12-31
Director/Board Member 59 2015-03-31
Date Insider Type Main position Quantity % Market Cap.
2/13/26 Free

Founder

589 0.0015%
2/13/26 Free

Director

589 0.0015%
2/13/26 Free

General Counsel

5,742 0.0146%
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%+0.73%+36.36%+31.98% 12.85B
+0.13%-0.21%+20.46%+27.05% 6.84B
+0.44%+8.84%+59.85%+39.36% 6.49B
+4.65%+9.00% - - 5.56B
-0.81%-0.00%-27.52%+49.71% 4.56B
+0.52%-2.95%-24.16%-18.36% 3.97B
-0.40%+8.11%+61.38%-43.69% 2.06B
+1.07%+6.95%+70.36%-9.19% 1.71B
-2.40%-11.26%-24.57%+123.26% 1.61B
+1.48%+3.58%-28.95%-41.80% 1.31B
Average +0.48%+2.79%+15.91%+17.59% 4.7B
Weighted average by Cap. +0.60%+2.66%+22.79%+25.20%

Financials

2026 *2027 *
Net sales 1.6B 1.38B 1.3B 1.18B 2.22B 152B 2.26B 15.29B 5.96B 76.16B 5.99B 5.86B 254B 1.8B 1.56B 1.46B 1.33B 2.51B 172B 2.55B 17.25B 6.72B 85.92B 6.76B 6.61B 287B
Net income 176M 153M 144M 131M 246M 16.82B 250M 1.69B 659M 8.42B 662M 648M 28.11B 242M 210M 197M 180M 338M 23.1B 343M 2.32B 905M 11.57B 910M 890M 38.61B
Net Debt -447M -388M -364M -331M -623M -42.61B -633M -4.28B -1.67B -21.34B -1.68B -1.64B -71.22B -729M -632M -593M -540M -1.02B -69.46B -1.03B -6.98B -2.72B -34.79B -2.74B -2.68B -116B
Logo Penumbra, Inc.
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets.
Employees
4,700
Date Price Change Volume
26-08-12 US$326.58 +0.09% 227,551
26-08-11 US$326.28 +0.09% 240,396
26-08-10 US$325.98 +0.41% 194,695
26-08-07 US$324.66 -0.06% 239,512
26-08-06 US$324.86 +0.51% 262,161
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
16
Last Close Price
326.58USD
Average target price
361.83USD
Spread / Average Target
+10.79%

Quarterly revenue - Rate of surprise